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Inﬂuenza, a respiratory disease caused by inﬂuenza viruses, still represents a major threat
to humans and several animal species. Besides vaccination, only two classes of drugs
are available for antiviral treatment against this pathogen. Thus, there is a strong need for
new effective antivirals against inﬂuenza viruses. Here, we tested Ladania067, an extract
from the leaves of the wild black currant (Ribes nigrum folium) for potential antiviral activity
against inﬂuenza A virus in vitro and in vivo. In the range of 0–1 mg/ml the extract showed
no cytotoxic effect on three cell lines and a CC50 of 0.5 ± 0.3 mg/ml, on peripheral
blood mononuclear cells. Furthermore, the extract did not inﬂuence the proliferative
status of human lymphocytes. In contrast, Ladania067 was highly effective (EC50 value:
49.3 ± 1.1 ng/ml) against the human pandemic inﬂuenza virus strain A/Regensburg/D6/09
(H1N1). The extract exhibited an antiviral effect when the virus was pre-incubated prior to
infection or when added directly after infection. No antiviral effect was foundwhen infected
cells were treated 2, 4, or 8 h after infection, indicating that Ladania067 blocks a very early
step in the virus infection cycle. In themouse infectionmodel wewere able to demonstrate
that an intranasal application of 500 μg Ladania067 inhibits progeny virus titers in the lung
up to 85% after 24 h.We conclude that the extract from the leaves of the wild black currant
may be a promising source for the identiﬁcation of new molecules with antiviral functions
against inﬂuenza virus.
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INTRODUCTION
Inﬂuenza virus is amajor plague with the potential to cause world-
wide epidemics. Infection with inﬂuenza A viruses can cause mild
clinical symptoms up to severe pathogenesis, an acute respiratory
distress symptom and death (Peiris et al., 2010). Though there
are some risk factors involved like pregnancy or chronic lung dis-
ease, the full reason for this heterogenic clinical picture remains
unknown. Clinical cases of inﬂuenza A virus infection manifest
in fever, cough, headache, and malaise (Louie et al., 2009; Bautista
et al., 2010; Kuiken et al., 2012).
Seasonal outbreaks and occasional pandemics of inﬂuenza
A viruses result in a high rate of morbidity and mortality in
humans all over the world. Moreover, the emergence of the
highly pathogenic avian H5N1 inﬂuenza virus, which is linked
to a mortality rate of nearly 60% in infected humans, as well
as the 2009 inﬂuenza pandemic (a global outbreak of a new
swine-origin strain of H1N1 inﬂuenza A virus) have high-
lighted the public health threat and the emergence of a novel
highly pathogenic pandemic inﬂuenza A virus strain (Dawood
et al., 2009; Neumann et al., 2009; World Health Organization,
2012).
The annual vaccination is the ﬁrst choice for protecting against
inﬂuenza viruses. Unfortunately, when the prediction for the
annual vaccine failed or in a pandemic situation, where in the
early phase no vaccine is available, the only choices against the
virus are antiviral drugs. Currently there are only two classes of
antiviral drugs available that are approved and licensed world-
wide against inﬂuenza A viruses for prophylactic and therapeutic
treatment in humans. Neuraminidase inhibitors block the func-
tion of the viral neuraminidase and consequently virus release.
Amantadine and Rimantadine are M2 ion channel blocker. Both
classes of drugs have in common that virus infection of the
host cell must occur before these drugs can function as antivi-
rals. The frequency of reports describing the appearance of
multidrug-resistant virus variants dramatically increased in the
nearer past (van der Vries et al., 2011; Hurt et al., 2012). In
this light it is disturbing that neuraminidase inhibitor resis-
tant H1N1 inﬂuenza virus strains from the 2009 pandemic are
already present (Yang et al., 2010; Meijer et al., 2011; Thorlund
et al., 2011). The Centers for Disease Control and Prevention
(CDC) reports that between 1 October 2008 and 30 Septem-
ber 2009, 1146 (99%) of 1157 seasonal inﬂuenza A (H1N1)
viruses, submitted from US public health laboratories, were
resistant to Oseltamivir. In addition, Sheu et al. (2010) char-
acterized in the same period 28 seasonal inﬂuenza A (H1N1)
viruses from 5 countries: the United States, Canada, China,
Kenya, and Vietnam that were dually resistant to Oseltamivir and
Adamantanes.
Moreover, there are very few antiviral drugs against inﬂuenza
viruses available that interacts with the viral hemagglutinin in
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order to interfere with virus entry. In one clinical trial the function
of carbosilane dendrimers as a hemagglutinin-inhibitor against
human inﬂuenza viruses was investigated (Oka et al., 2008, 2009).
In its actual research agenda the World Health Organization
(WHO) called up to optimize the effectiveness of current and
novel antiviral treatments through development of new formu-
lations, delivery routes, or novel defense mechanisms including
natural products.
There are many reports describing strong antiviral activ-
ity of traditional medicinal plants, indicating a rich source of
novel molecules against inﬂuenza virus strains (Wang et al., 2006;
Kitazato et al., 2007; Fiore et al., 2008). Recently, we have reported
that the polyphenol rich plant extract, CYSTUS052 showed antivi-
ral activity against inﬂuenza A viruses in cell culture and in mice
(Droebner et al., 2007, 2009; Ehrhardt et al., 2007). Moreover, the
antiviral activity of CYSTUS052 against seasonal inﬂuenza virus
and common colds was also demonstrated in humans (Kalus et al.,
2009). Notable, no drug-resistant virus variants due to CYS-
TUS052 treatment were found (Ehrhardt et al., 2007). In order
to discover novel antiviral drugs against inﬂuenza viruses and
extract from the leaves of wild black currant (Ribes nigrum folium)
was tested. In the recent past Ribes nigrum folium came into the
focus to gain beneﬁt in human health. The anti-inﬂammatory
property of this plant is due the to fact that it is very rich
in tannins such as prodelphinidins and proanthocyanidins (Tits
et al., 1992; Garbacki et al., 2002, 2004) as well in phenolics and
antioxidants (He et al., 2010; Tabart et al., 2011). These phe-
nolic compounds, such as ﬂavonoids have been demonstrated
to serve anti-allergenic, anti-oxidative, anti-inﬂammatory, anti-
proliferative, anti-bacterial, and anti-viral (Gallina et al., 2011;
Korkina et al., 2011; Kostyuk et al., 2011; Zandi et al., 2011; Costa
et al., 2012; Ikuta et al., 2012; Pastore et al., 2012).
In the present study, we investigated the effectiveness of
Ladania067 against the human inﬂuenza A pandemic strain
A/Regensburg/D6/09 (H1N1, RB1) in vitro and in vivo demon-
strating that Ladania067 treatment resulted in reduced virus
replication without toxic effects.
MATERIALS AND METHODS
COMPOUNDS
Ladania067, the water-soluble extract form the leaves of wild black
currant (Ribes nigrum folium) was supplied and originally devel-
oped by Dr. Pandalis Naturprodukte GmbH & Co. KG; Glandorf,
Germany and supplied as a liquid formulation, according to the
manufactories protocol. It was further lyophilized at the Inter-
faculty Institute for Cell Biology, Department of Immunology,
Eberhard Karls University Tuebingen, Germany. The Ladania067
powder was dissolved in sterile phosphate buffered saline (PBS) or
cell culture media in concentration as indicated.
Tamiﬂu® was purchased from Roche Diagnostics (Mannheim,
Germany) and dissolved in water to a working concentration of
5 mg/kg.
VIRUS
The human pandemic inﬂuenza virus strain A/Regensburg/D6/09
(H1N1, RB1) was obtained from the Robert-Koch-Institute, Fed-
eral Institute for Public Health, Berlin, Germany. The virus was
further propagated in human lung adenocarcinoma epithelial cells
(A549) at the Interfaculty Institute for Cell Biology, Department
of Immunology, Eberhard Karls University Tuebingen, Germany.
Therefore, 1 day prior infection A549 cells were seeded in a cell
culture ﬂask to a density of approximately 40%. The day after, cells
were washed with PBS and infected with the RB1 virus at a mul-
tiplicity of infection (MOI) of 5. After several days, depending on
the cytopathogenic effect (CPE), supernatant was harvested. The
progeny virus titer was measured by AVICEL® plaque assay.
INFLUENZA VIRUS TITRATION (AVICEL® PLAQUE ASSAY)
To assess the number of infectious particles in the samples, a
plaque assay using AVICEL® was performed in 96-well plates
as described previously (Haasbach et al., 2011). Brieﬂy, Madin-
Darby canine kidney (MDCK II)-cells grown to conﬂuency in
96-well dishes, then they were washed with PBS and infected
with serial dilutions of the supernatants in PBS/BA for 30 min at
37◦C. After incubation cells were overlaid with overlay-medium
[1:1, MEM-medium containing 0.2% BSA, antibiotics and 2.5%
AVICEL®-Medium (FMC BioPolymer, Philadelphia, PA, USA)]
for 24 h. Afterward, virus-infected cells were immunostained by
incubating for 1 h with a monoclonal antibody speciﬁc for the
inﬂuenza A virus nucleoprotein (Serotec, Duesseldorf, Germany),
followed by 30 min incubation with peroxidase-labeled anti-
mouse antibody (DIANOVA, Hamburg, Germany) and 10 min
incubationwith True BlueTM peroxidase substrate (KPL,Gaithers-
burg, MD, USA). Stained plates were scanned on a ﬂat bed
scanner and the data were acquired by Corel DRAW 9.0 soft-
ware. To deﬁne the titer of progeny virus, the foci of infected
cells for every sample in each well of the 96-well plates were
counted and multiplied with the dilution factor. The mean val-
ues were taken from the ﬁnal number of foci in each well. The
viral titers are shown as the logarithm to the base 10 of the mean
values.
MEASUREMENT OF PHARMACOLOGICAL PARAMETERS IN VITRO
To determine the effective concentration 50% (EC50) of Lada-
nia067 against inﬂuenzaAvirus in vitrowe infected 2× 105 human
lung adenocarcinoma epithelial cells (A549) per well in a 24-well
plate with RB1 (MOI of 0.001). After 30 min virus inoculum was
discarding and the infected cells were treated with Ladania067
by adding the plant extract to the culture medium in different
concentrations (0–1 mg/ml). Progeny virus titers in the super-
natant of infected and treated cells were measured by plaque assay
as described in 2.3. Each experiment was repeated three times
independently with each comprising triplicates.
The cytotoxic concentration 50% (CC50) of Ladania067 was
determined in A549, MDCK II and cervical cancer (HeLa) cells as
well in human peripheral blood mononuclear cells (PBMCs). All
cell types were seeded in 96-well plates with a density of 1.5 × 105
(5 × 105 PBMCs) before incubation with different Ladania067
concentrations (0–1 mg/ml) for 24 h. After incubation, cyto-
toxic effects were measured by a water-soluble tetrazolium salt
(WST-1) assay according to the manufactures protocol (Roche
Diagnostics, Mannheim, Germany). All experiments were per-
formed in triplicates. Results evaluated by GraphPad prism 5.0
software.
Frontiers in Microbiology | Virology April 2014 | Volume 5 | Article 171 | 2
Haasbach et al. Ladania067 against inﬂuenza A virus
LYMPHOCYTE PROLIFERATION ASSAY AND FLOW CYTOMETRY
Peripheral blood mononuclear cells were isolated from healthy
donors using Ficoll-Hypaque density gradient centrifugation
(PAA Laboratories, Pasching, Austria). The cells were fur-
ther incubated with RPMI 1640 medium supplemented with
Penicillin/Streptomycin and autologous plasma.
Cells were transferred into 24-/ or 96-well cell culture plates
and incubatedwith indicated concentrations of Ladania067. Poke-
weed mitogen (PWM; 40 μg/ml) was used as a non-speciﬁc
positive control (Biochrom, Berlin, Germany). For the prolif-
eration assay, the stimulated cells were incubated for 6 days
with Ladania067 (800, 80, 8, 0.8, 0.08 μg/ml) at 37◦C and 5%
CO2. After incubation, cells were pulsed with 0.5 μCi (2.22–
3.33 TBq/mmol) of 3H-thymidine and further incubated for
16 h. Afterward cells were harvested and the 3H-thymidine
incorporation was measured using the MicroBeta2TM Microplate
Counter (Perkin Elmer, Waltham, MA, USA). For the ﬂow
cytometry analysis, stimulated, untreated or Ladania067 treated
cells were incubated for 1 day at 37◦C and 5% CO2. After
incubation cells were stained with α-CD4-PE, α-CD8-PerCP,
α-CD3-FITC, α-CD69-APC, α-CD19-FITC, α-CD45-PerCP, α-
CD56-PE, and α-CD69-APC (Miltenyi Biotec, Bergisch Gladbach,
Germany). The amount of activation in all stained cell types
was measured with BD FACSCantoIITM ﬂow cytometer (Bec-
ton Dickinson, Heidelberg, Germany) using the FACS software
DivaTM. The data were analyzed using the FlowJo 7.6.3 soft-
ware (TreeStar, Ashland, OH, USA). All experiments were done in
triplicates.
MODE OF ACTION STUDY
The therapeutic effect of Ladania067 was determined by infec-
tion of A549 cells with RB1 (MOI of 0.001) and treatment with
100μg/mlLadania0670, 2, 4, or 8hpost-infection. After 24h incu-
bation, progeny viruswas determined in the supernatant by plaque
assay. Pre-incubated cells or virus with Ladania067 were examined
to show the prophylactic effect of Ladania067. A549 cells were
treated 1hprior to infectionwith 100μg/mlLadania067orMOCK
treated at 37◦C and 5% CO2. After 1 h, Ladania067 was aspirated
and cells were washed and infected with RB1 (MOI 0.001). The
virus titers in supernatants were determined after 24 h. To iden-
tify the direct effect of Ladania067 against the virus, we incubated
the virus with or without 100 μg/ml Ladania067 at 37◦C and 5%
CO2 for 2 h. Afterward A549 cells were infected either with the
Ladania067-incubated virus or with the mock-incubated virus for
24 h. Supernatants were taken and assayed for progeny virus by
plaque assay.
VIRUS INOCULATION OF MICE
Six to eight week-old female C57BL/6 mice were obtained from
Janvier (St Berthevin Cedex, France). Before intranasal inoc-
ulation with the inﬂuenza A virus strain A/Regensburg/D6/09
(H1N1, RB1), mice were anesthetized by intraperitoneal injection
of 150 μl of a ketamine (Sanoﬁ)-rompun (Bayer)-solution (equal
amounts of a 2%-rompun-solution and a 10%-ketamin-solution
were mixed at the rate of 1:10 with PBS).
To determine the 50% mouse lethal dose (MLD50), ﬁve
groups of ﬁve mice were inoculated intranasally with a 10-fold
serial dilution of virus. The MLD50 was calculated by the
method of Reed and Muench (1938). The MLD50 of RB1 in
C57BL/6 mice is 3 × 104 pfu/50 μl. All animal studies were
approved by the Institutional Animal Care and Use Committee of
Tuebingen.
LADANIA067- AND TAMIFLU® -TREATMENT OF MICE AND VIRUS
INFECTION
Thirty minutes prior to viral inoculation, mice were anesthetized
by intraperitoneal injection of ketamine/rompun and treated
intranasally either with 50 or 500 μg Ladania067 in 50 μl PBS.
The control group received 50 μl of the solvent (PBS). Mice were
infected intranasally with the 5-fold MLD50 of RB1. Lungs of
Ladania067-treated and solvent-treated control mice were col-
lected 24 h after infection and viral titers were determined by
plaque assay.
For Tamiﬂu®-treatment C57BL/6 mice were treated 12 h prior
to infection per os with 5 mg/kg Tamiﬂu® in 200 μl water. The
control group received 200 μl of the solvent (water). Immediately
before infection with the 5-fold MLD50 of RB1, mice were treated
again. Twelfth hours after infection mice were treated the third
time. Lungs were collected 24 h after infection and viral titers were
determined by plaque assay.
For the survival experiment, treatment ofmicewithLadania067
was performed in an inhalation chamber (ACTIVAERO GmbH,
Gemuenden/Wohra, Germany), to assure delivery directly into the
lung since. Fourmice were treated each in a single inhalation tube.
Four of those single inhalation tubes were connected to a PARI®
LC SPRINT nebulizer (PARI® GmbH, Starenberg, Germany). The
ﬂow rate in the inhalation chamber was set up to 8 l per min.
300 mg/6 ml PBS or buffer solution alone were given for 15 min
to the chamber with a constant pressure of 2.0 bars. Treatment
of mice was performed for ﬁve consecutive days twice daily every
12 h starting 6 h after infection.
For the determination of the clinical score the following dis-
ease symptoms were found and deﬁned in mice after inﬂuenza
virus infection: ruffed fur, teeth crunching, ataxia, dyspneic, con-
junctivitis. If mice showed one of these symptoms they got one
score; 2 symptoms = score 2; 3 and more symptoms = score 3;
death = score 4. Note, the score 4 was kept throughout the 10 days
observation period. Score represents the mean value of the group.
Furthermore, mice were weighted daily. When mice died, the
bodyweight was kept throughout the 10 days observation period.
STATISTICAL ANALYSIS
Error bars were given as the SEM. For the calculation of the
signiﬁcance of the t-test was performed for two different and
ANOVA analysis was carried out for more than two different
groups. P values of ≤0.05 are referred to as ∗ and <0.01 as ∗∗.
Analyses were performed using GraphPad Prism version 5.0 for
Windows (GraphPad Software, San Diego, CA, USA) or FlowJo
7.6.3 software (TreeStar, Ashland, OH, USA).
RESULTS
LADANIA067 EXHIBIT NO CYTOTOXIC EFFECTS IN CELL CULTURE
To investigate whether treatment of Ladania067 would result
in cytotoxic effects, the cytotoxic concentration 50% (CC50) of
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FIGURE 1 | Ladania067 treatment shows no cytotoxic effects in vitro.
The cytotoxic concentration 50% (CC50) of Ladania067 was determined
in MDCK (A), A549 (B), HeLa (C), and PBMCs (D). Cells were
incubated with Ladania067 (0–1 mg/ml) for 24 h. After incubation, cell
viability was measured by WST-1 assay regarding manufactory guidelines
(n = 3).
the extract was determined in four different cell types. MDCK,
A549, PBMCs and HeLa cells were treated with Ladania067 in
a concentration range of 0 to 1 mg/ml. After incubation period
of 24 h the cell viability was measured by the WST-1 assay. The
Ladania067 extract showed no cytotoxic effects against MDCK
(Figure 1A), A549 (Figure 1B), or HeLa (Figure 1C) cells in the
concentration range described. Consequently the CC50 value was
greater than>1mg/ml. Only with human PBMCs we could deter-
mine a CC50 value in the low mg range (CC50 = 0.5 ± 0.3 mg/ml;
Figure 1D). These results indicate that Ladania067 either exhibits
no cytotoxic effects in most cell types or only acts cytotoxic in
human PBMCs in very high concentrations.
IMMUNE CELLS ARE NOT AFFECTED BY LADANIA067 TREATMENT
Due to the fact that Ladania067 demonstrated a cytotoxic effect
on human PBMCs we further wanted to scrutinize this effect and
raise the question whether Ladania067 treatment would inﬂuence
human lymphocyte proliferation. Therefore, lymphocytes from
human whole blood were isolated and treated with different con-
centrations of Ladania067 (0–800 μg/ml) for 6 days following by
16 h incubation with 3H-thymidine. The concentrations used for
treatment also included one concentration above the CC50 value
(800 μg/ml).
First, we tested a possible inﬂuence of Ladania067 on the prolif-
eration of human lymphocytes. Therefore, these cells were treated
with different concentrations (0.08–800 μg/ml) or left untreated
in order to calculate a stimulation index. As a positive control the
cells were treated with PWM, a strongmitogenic stimulus for lym-
phocytes. While PWM readily induced lymphocyte proliferation
as expected no enhanced proliferation of lymphocytes was found
after Ladania067 treatment (Figure 2A). Interestingly, even after
treatment with 800 μg/ml 3H-thymidine counts were comparable
to the levels in cells treated with lower amounts of Ladania067
or left untreated, indicating neither a proliferative nor a toxic
effect.
In addition, ﬂow cytometry analysis was performed in order to
evaluate a proliferative effect of Ladania067 against single immune
cell subtypes.While PWM treatment resulted in activation of 20%
of CD4+ T cells, almost no activatedCD4+ T cells were found after
Ladania067 treatment (Figure 2B). A similar picturewas found for
theCD8+ T cell and B cell population,whereas the amount of acti-
vated CD8+ T cells and B cells was generally increased compared
to the CD4+ T cell population (Figures 2C,D). When natural
killer (NK) cells were treated with 120 μg/ml of Ladania067 a
slight, but not signiﬁcant increase of activated NK cells was found
(Figure 2E). Based on these results we conclude that treatment
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Table 1 | Pharmacological parameters of Ladania067 in vitroa.
Ladania067
EC50 [ng/ml] CC50 [mg/ml] SI
RB1 49.3 ± 1.1 >1 >20.408
aHuman lung adenocarcinoma epithelial cells (A549).
with Ladania067 neither induces cytotoxic effects nor activates
lymphocytes in vitro.
LADANIA067 INHIBITS INFLUENZA VIRUS REPLICATION IN VITRO
Next, we examined the antiviral properties of Ladania067 against
the pandemic inﬂuenza A virus A/Regensburg/D6/09 (H1N1,
RB1) in cell culture. Ladania067 was added to the A549 cells in
different concentrations ranging from 0 to 10 mg/ml directly after
there infection. The ability to reduce the virus titer was analyzed
by measurement of progeny virus in the supernatant after 24 h of
culturing. A concentration as low as 1 μg/ml of Ladania067 was
sufﬁcient to reduce virus titers by almost 90%. To determine the
EC50 of Ladania067 against RB1 infected A549 cells the percent-
age of virus titer reduction of all concentrations used compared to
untreated controls were analyzed using GraphPad Prism software.
The experiment was performed three times with similar results
(Figure 3). The results are presented in A and B by sigmoid func-
tion and in C and D in bar graphs. The mean values of these three
experiments were plotted to calculate the EC50 value. As shown in
Figure 3B the EC50 value of Ladania067 of RB1-infectedA549 cells
is 49.3 ± 1.1 ng/ml compared to a CC50 value for Ladania067 on
A549 cells of>1mg/ml (Figure 1B). The EC50 and theCC50 values
allow to calculating the selective index (SI = CC50/EC50), which is
the amountof drug that causes the therapeutic effect to the amount
that causes cytotoxic side effects. In the present experiment the
SI of Ladania067 against RBI infected A549 cells is >20.408
(Table 1). This index indicates a very broad therapeutic window of
Ladania067.
LADANIA067 BLOCKS A VERY EARLY STEP IN THE VIRUS INFECTION
CYCLE
Now the question arises at which stage of the virus life cycle Lada-
nia067 inhibits inﬂuenza virus replication. First the progeny virus
release of inﬂuenza A virus infected cells treated with 100 μg/ml
Ladania067 was determined either direct after infection (compa-
rable to 3.3) or 2, 4, or 8 h post-infection. A strong reduction of
virus titer (1.7 ± 0.2 log10 pfu/ml) could only be observed when
Ladania067 was added directly after infection (Figures 4A,B ﬁrst
left white bar). Ladania067 treatment at 2, 4, or 8 h p.i. revealed
no antiviral effect compared to untreated control cells as shown
in virus titer log10 pfu/ml (Figure 4A, second to forth white bar
from the left) and in% reduction compared to control (Figure 4B,
second to forth white bar from the left).
In another experiment the A549 cells were pre-incubated
with Ladania067 at a concentration of 100 μg/ml for one hour.
Subsequently, cells were infected in the absence of Ladania067.
Thereafter, the supernatant of Ladania067 treated A549 cells
FIGURE 2 | Continued
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FIGURE 2 | Continued
Immune cells are not affected by Ladania067. (A) 3H-thymidine
incorporation assay was performed with fresh human isolated PBMCs.
Cells were treated for 6 days with different concentrations of Ladania067
(800, 80, 8, 0.8, 0.08 μg/ml). PWM, (black bar; 40 μg/ml) was used as a
non-speciﬁc positive control. After incubation cells were pulsed for 16 h
with 3H-thymidine. Stimulation index were calculated by dividing treated
cells to spontaneous release. (B) Flow cytometry analysis of different
activated immune cell subtypes, CD4+ (B) and CD8+ T lymphocytes (C), B
cells (D) and NK cells (E) after 1 day Ladania067 treatment (120, 12, 1.2,
0.12, 0.012 μg/ml). Values are given as percent of total gated. All results
represent three different donors.
(Figures 4C,D white bar) were analyzed 24 h p.i. for progeny
virus release in comparison to virus infected but untreated con-
trol cells (Figures 4C,D black bar). Only a marginal reduction of
progeny virus titer was found, when cells were pre-incubated with
Ladania067. After virus pre-incubation for 2 h with or without
100 μg/ml Ladania067 at 37◦C and 5% CO2 cells were infected
either with pre-treated or non-pre-treated virus and the virus titer
was determined after 24 h. A strong virus titer reduction of more
than 95% could be observed when the inﬂuenza virus was pre-
incubated with Ladania067 prior to infection (Figures 4E,F white
bar), in comparison to non-pre-treated virus (Figures 4E,F black
bar). Taken together, these experiments indicate that Ladania067
most probably interacts with the invading pathogen rather than
with the host cell.
SINGLE ADMINISTRATION OF LADANIA067 REDUCES VIRUS
PRODUCTION IN THE LUNGS OF H1N1-INFECTED MICE
After successfully demonstrating the antiviral capacity of Lada-
nia067 in cell culture we investigated the potential of the extract to
reduce inﬂuenza A virus infectivity in the mouse model. In addi-
tion we wanted to compare the antiviral effect of Ladania067 with
the bona ﬁde antiviral, Tamiﬂu®. Therefore, C57BL/6 mice were
treated via the intranasal route with either 50 or 500 μg Lada-
nia067 dissolved in 50 μl PBS or with 50 μl PBS (Mock) alone
30 min prior to infection. Thereafter, mice were infected with the
5-foldMLD50 of RB1. The lungs of Ladania067-treated andmock-
treated control mice were collected 24 h p.i. and virus titers were
determined by plaque assay. In the lungs of mock-treated mice a
virus titer of 5.6 ± 0.01 log10 pfu/ml was noted. Mice treated with
500 μg Ladania067 showed a virus titer of 4.7 ± 0.49 log10 pfu/ml,
a reduction of more than 85% compared tomock-treatedmice. In
contrast,mice treatedwith 50μg Ladania067 showedno reduction
of virus titer in the lung (Figures 5A,B). These data indicate that
there is a dose dependent effect of Ladania067 against inﬂuenza A
FIGURE 3 | Ladania067 reduces influenza virus replication in vitro.The
effective concentration 50% (EC50) of Ladania067 was measured by
treatment of inﬂuenza A virus A/Regensburg/D6/09 (H1N1, RB1) infected
A549 cells. Cells were infected with RB1 (MOI 0.001) and further treated with
different concentrations of Ladania067 (0–1 mg/ml) for 24 h. Progeny virus
titer was determined by plaque assay. (A) Results of three independent
experiments, (B) mean of three independent experiments, calculated by
GraphPad Prism software. (C: pfu/ml) and (D: %) shows results in bar charts.
For calculation, each experiment was performed three times independently
with each comprising triplicates.
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FIGURE 4 |Therapeutic treatment of RB1 infected A549 cells (MOI
0.001) 0, 2, 4, or 8 h past infection with 100 μg/ml Ladania067 or
solvent for 24 h. After incubation progeny virus titer was measured by
plaque assay (A: in pfu/ml, B: in %). Treatment of A549 cells prior to
infection was performed with 100 μg/ml Ladania067 or solvent for 1 h.
After pre-incubation, Ladania067 was aspirated and cells were washed and
infected with RB1 (MOI 0.001). Following 24 h incubation progeny virus
titer was measured by plaque assay (C: in pfu/ml, D: in %). Prior to
infection, virus was 2 h per-incubated with 100 μg/ml Ladania067 or solvent
at 37◦C and 5% CO2. After incubation A549 cells were either infected with
Ladania067-incubated or solvent-incubated virus for 24 h. After incubation
progeny virus titer was measured by plaque assay (E: in pfu/ml, F: in %).
For calculation, the experiment was performed two times independently
with each comprising triplicates (*p < 0.05).
virus in vivo. Treating inﬂuenza virus infected mice with Tamiﬂu®
(Figures 5C,D), we found a reduction of progeny virus in the lungs
of 1.0 log10 pfu/ml which is similar to the results of Ladania067.
Therefore, in our mouse model the antiviral effect of Ladania067
is comparable with the effect of the bone ﬁde antiviral Tamiﬂu®.
Moreover, we investigated if Ladania067 would also inﬂuence the
survival of RB1 infected mice. To assure deposition of the extract
in the lung, Ladania067 was supplied via an aerosol route as per-
formedbefore (Droebner et al., 2007). Fourmicewere infected and
treated with 300 mg/6 ml Ladania067 for 15 min (Figures 5E–G;
black dotted line) or with PBS (Figures 5E–G; black solid line) for
5 days twice daily starting six hour after infection. After RB1 infec-
tion both groups of mice were loosing weight, but the Ladania067
treated animals stabilized the bodyweight by day 6 p.i. (Figure 5E).
Onset of clinical symptoms was at day 4 p.i. in both groups.
While the symptoms increased in the untreated group continu-
ously to score four (death), disease symptoms decreased in the
Ladania067 treated group by day 7 p.i. (Figure 5F). All four
untreated mice died between days 6 and 7, while only one out of
four animals from the Ladania067 treated group died at day 8 p.i.
(Figure 5G).
DISCUSSION
There is still an urgent medical need for the development of new
strategies to battle inﬂuenza virus infection. Antiviral drugs are
the only source to ﬁght the disease, when no vaccine is available,
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FIGURE 5 | Ladania067 administration reduces progeny virus titer in
the lungs of infected mice. C57BL/6 mice were treated 30 min prior
to infection via the intranasal route with either 50 μg (four mice) or
500 μg (ﬁve mice) Ladania067 in 50 μl PBS. The control group (three
mice) received 50 μl of the solvent (PBS). Within the anesthesia, mice
were infected intranasally with the 5-fold MLD50 of RB1. Lungs were
collected 24 h after infection and viral titers were determined by
plaque assay (A: in pfu/ml, B: in %). Four C57BL/6 mice per group
were treated 12 h prior to infection per os with 5 mg/kg Tamiﬂu®
in 200 μl water. The control group received 200 μl of the solvent
(water). Immediately before infection with the 5-fold MLD50 of RB1,
mice were treated again. Twelfth hours after infection mice were
treated the third time. Lungs were collected 24 h after infection and
viral titers were determined by plaque assay (C: in pfu/ml, D: in %).
P values of <0.05 are referred to as ∗ and <0.01 as ∗∗. For survival
experiments (E–G) four C57BL/6 mice per group were either treated
with 500 μg Ladania067 via the aerosol route twice daily for 5 days
beginning with the day of infection (black solid line) or with PBS
(black dotted line). Mice were weighted daily (E) and disease
symptoms were monitored (F). While untreated mice died between
days 6 and 7 p.i. only one out of four from the 500 μg Ladania067
treated group died (G).
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like in the early phase of a pandemic or when the prediction for
the composition of the seasonal inﬂuenza vaccine fails. In 2010 the
WHO suggested in their inﬂuenza research agenda the develop-
ment of novel and effective treatment strategies including natural
products (WorldHealth Organization, 2010). This prompted us to
investigate the antiviral activity of plant extracts against inﬂuenza
virus infection.
In the present work we have chosen an water-soluble extract
from the leaves of the black current (Ribes nigrum folium) because
this plant already has a strong record in the literature for its
beneﬁcial effects for human health. Ribes nigrum is very rich in
tannins in particular on prodelphinidins and proanthocyanidins
like epigallocatechin gallate (EGCG). It is well known that these
tannins have anti-inﬂammatory and anti-oxidant properties (Tits
et al., 1992; Garbacki et al., 2002, 2004). Moreover, Ribes nigrum is
very rich in phenolic compounds in particular ﬂavonoids which
are very well known for their anti-allergenic, anti-oxidative, anti-
inﬂammatory, anti-proliferative, and antiviral properties (Gallina
et al., 2011; Korkina et al., 2011; Kostyuk et al., 2011; Zandi et al.,
2011; Costa et al., 2012; Pastore et al., 2012). In addition, EGCG
shows anti-inﬂuenza virus activity (Song et al., 2005; Kim et al.,
2013).
In previous studies with a polyphenol-rich extract from the
plant Cistus incanus CYSTUS052, we were able to demonstrate a
pronounced antiviral effect against inﬂuenza A virus in vitro and
in vivo. The underlining mechanism is the blocking of virus entry.
This blockade is most due to an unspeciﬁc anti-adhesion effect
on the pathogen since a speciﬁc interaction with cellular receptors
in particular with sialic acid receptors could not be demonstrated
(Droebner et al., 2007; Ehrhardt et al., 2007).
In the present work we were able to demonstrate that the
extract from Ribes nigrum folium (Ladania067) has strong antivi-
ral activity against inﬂuenza virus. The EC50 value of Ladania067
in RB1-infected A549 cells was 49.3 ± 1.1 ng/ml. This very potent
activity leads to the assumption that the secondary plant metabo-
lites responsible for the antiviral activity must be present in high
concentrations. In contrast, the CC50 value on primary human
PBMCs was 0.5 ± 0.3 mg/ml. No toxic effects were found in
all cell lines tested, when concentrations of up to 1 mg/ml were
used. Moreover, neither a stimulatory nor an inhibitory inﬂu-
ence on primary human lymphocytes could be measured. From
these data one can conclude that Ladania067 has a very broad
SI. As demonstrated here, on human A549 cells the SI value is
>20.408. The results also demonstrated that the antiviral func-
tion was only present, when the extract was added to the cell
culture system prior to infection. Treatment that started two
hours after infection was not successful in protecting the cells.
In contrast, when the virus was pre-incubated with Ladania067
a strong reduction of virus titer was present. From these results
we conclude that Ladania067 has virucidal properties but might
also blocks the virus replication in a very early step of infection;
most probably by a similar anti-adhesive manner like CYSTUS052
(Droebner et al., 2007).
It is well known that plant extracts can efﬁciently inhibit viral
attachment and penetration. In the case of herpes simplex virus
type-1 (HSV-1) there were different plant extracts, Myrotham-
nus ﬂabellifolia, Rumex acetosa L., or Azardirachta indica, which
act as a blocking agent of viral adsorption and/or penetration
(Tiwari et al., 2010; Gescher et al., 2011). Nevertheless, sec-
ondary plant metabolites such as theaﬂavin, pentagalloylglucose,
or glycyrrhizin can also function in a direct manner. Theaﬂavin
is a compound that is able to inhibit the inﬂuenza virus replica-
tion via interference with the haemagglutinin synthesis. Moreover,
it can also decrease the expression level of the inﬂammatory
cytokine IL-6 during viral infection (Zu et al., 2012). Penta-
galloylglucose and glycyrrhizin also show anti-inﬂuenza virus
properties which are mediated by reduced activation of NFκB,
JNK, and p38 or an interaction with the cell membrane which
most likely results in reduced endocytotic activity and hence
reduced virus uptake (Wolkerstorfer et al., 2009; Liu et al., 2011;
Michaelis et al., 2011). In another study it was shown that EGCG,
epicatechin gallate (ECG), and epigallocatechin (EGC) demon-
strate antiviral effect against inﬂuenza A and B viruses. This
is mediated by speciﬁc interaction with the hemagglutinin and
by altering the physical properties of viral membrane (Song
et al., 2005). Resveratrol, another polyphenol found in grapes
strongly inhibited the replication of inﬂuenza virus in cell cul-
ture by blockade of the nuclear cytoplasmic translocation of
the viral ribonucleoprotein complex, by reducing the expres-
sion of late viral proteins and by inhibition of protein kinase
C (PKC) activity and PKC-dependent pathways (Palamara et al.,
2005).
Due to the data obtained from the inﬂuence of Ladania067 on
lymphocyte proliferation or activation we can exclude such direct
effect. In particular alterations on cytokine expression would have
an effect on the tested human PBMCs. This was not the case at
least for the activation or proliferation of CD4+ and CD8+ T
lymphocytes, NK or B cells (Figure 2). Therefore, we hypothesize
that the full plant extract Ladania067 rather interacts with the
pathogen to block virus attachment to the target cell.
In order to validate our in vitro ﬁndings animal experiments
were performed in the mouse, where we were able to demonstrate
that treatment with the extract of Ribes nigrum folium was suc-
cessful in reducing the amount of inﬂuenza virus in the lung. We
decided to treat mice via the intranasal route, since this is the nat-
ural route of inﬂuenza virus infection and the extract was directly
delivered to the place of infection andwere able to show that Lada-
nia067 exhibits similar antiviral effects in vivo as Tamiﬂu®. The
results indicate that the ﬁndings from our in vitro experiments can
be transferred to the situation in vivo. Treatment of mice started
prior to infection and moreover, best antiviral effects in vitro were
found when treatment was started before infection. Furthermore,
survival experiments were performed indicating protection from
death after Ladania067 treatment. From these data we conclude
a possible prophylactic function of this plant extract that is non-
toxic in cell culture and also a therapeutic function in early stages
of the disease.
In summary, treatment with the plant extract Ladania067 from
the leaves of the black currant, leads to a virus reduction in vitro
and in the mouse model. At the present stage we conclude that
Ladania067 could be a very promising extract for the develop-
ment of a new, safe and efﬁcient antiviral compound, based on
herbal products. It can act as a novel defense strategy against
inﬂuenza virus infection, even tough the effect is mostly virucidal.
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Thus the compound might be used prophylactically but also in an
early therapeutic setup to prevent the virus spead. In addition to
the virucidal functions our ﬁndings support the work of Ehrhardt
et al. (2013), which showed that the protective effect of Ladania067
appears to bemainly due to interferencewith virus internalization.
Furthermore, this work demonstrated antiviral activity of Lada-
nia067 against two other viruses A/FPV/Bratislava/79 (H7N7) and
A/PuertoRico/8/34 (H1N1). Thus, at this stage of the development
it is full in line with the recommendation of the WHO inﬂuenza
research agenda.
This study is another example that plant extracts are able to
inhibit inﬂuenza A virus infection in vitro and in vivo. From
these ﬁndings one might take two further research directions.
One would be to further characterize and identify the compounds
with antiviral properties in the extract. The antiviral activity of
EGCG was already described. Nevertheless it is of great impor-
tance to answer the question whether only one compound, or
several closely related compounds, or a composite activity of sev-
eral different molecules are responsible for the observed antiviral
activity and whether is activity is selective for inﬂuenza viruses?
Moreover, since the extract is already used in human nutrition and
shows no adverse effect a clinical pilot study to would give further
information on the potency of the full extract to protect against
inﬂuenza virus infection.
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